UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 84

Sortiert nach

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

Diabetes (New York, N.Y.), 2018-08, Vol.67 (8), p.1471-1480

2018

Link zum Volltext

Verfügbarkeit prüfen

The β-Cell in Type 1 Diabetes Pathogenesis: A Victim of Circumstances or an Instigator of Tragic Events?

Diabetes (New York, N.Y.), 2022-08, Vol.71 (8), p.1603-1610

2022

Link zum Volltext

Verfügbarkeit prüfen

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes

Diabetes (New York, N.Y.), 2021-12, Vol.70 (12), p.2922-2931

2021

Link zum Volltext

Verfügbarkeit prüfen

731-P: The Effect of Abatacept upon Glucose and C-Peptide Endpoints at One Year of Treatment and on Follow-up

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Diabetes (New York, N.Y.), 2013-11, Vol.62 (11), p.3766-3774

2013

Link zum Volltext

Verfügbarkeit prüfen

Natural History of β-Cell Function in Type 1 Diabetes

Diabetes (New York, N.Y.), 2005-12, Vol.54 (suppl 2), p.S32-S39

2005

Link zum Volltext

Verfügbarkeit prüfen

Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances

Diabetes (New York, N.Y.), 2019-07, Vol.68 (7), p.1366-1379

2019

Link zum Volltext

Verfügbarkeit prüfen

A Call for Improved Reporting of Human Islet Characteristics in Research Articles

Diabetes (New York, N.Y.), 2019-02, Vol.68 (2), p.239-240

2019

Link zum Volltext

Verfügbarkeit prüfen

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

Diabetes (New York, N.Y.), 2012-08, Vol.61 (8), p.2066-2073

2012

Link zum Volltext

Verfügbarkeit prüfen

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protégé Trial

Diabetes (New York, N.Y.), 2013-11, Vol.62 (11), p.3901-3908

2013

Link zum Volltext

Verfügbarkeit prüfen

Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective

Diabetes (New York, N.Y.), 2022-04, Vol.71 (4), p.610-623

2022

Link zum Volltext

Verfügbarkeit prüfen

Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade: Evidence of Improved Immune Regulation

Diabetes (New York, N.Y.), 2012-01, Vol.61 (1), p.145-154

2012

Link zum Volltext

Verfügbarkeit prüfen

276-OR: A 2-Dimensional (2D) Analysis of Glucose and C-Peptide Shows a Teplizumab Effect in Individuals at Risk for Type 1 Diabetes (T1D) 3 Months after Treatment

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Link zum Volltext

Verfügbarkeit prüfen

11-OR: Assessments of Prediagnostic Metabolic Measures as Surrogate Endpoints for Type 1 Diabetes (T1D) Prevention Trials

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience

Diabetes (New York, N.Y.), 2018-07, Vol.67 (7), p.1216-1225

2018

Link zum Volltext

Verfügbarkeit prüfen

β-Cell Mass and Type 1 Diabetes : Going, Going, Gone?

Diabetes (New York, N.Y.), 2008-11, Vol.57 (11), p.2883-2888

2008

Link zum Volltext

Verfügbarkeit prüfen

How Does Type 1 Diabetes Develop?: The Notion of Homicide or β-Cell Suicide Revisited

Diabetes (New York, N.Y.), 2011-05, Vol.60 (5), p.1370-1379

2011

Link zum Volltext

Verfügbarkeit prüfen

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials

Diabetes (New York, N.Y.), 2020-08, Vol.69 (8), p.1827-1832

2020

Link zum Volltext

Verfügbarkeit prüfen

Carbonyl Posttranslational Modification Associated With Early-Onset Type 1 Diabetes Autoimmunity

Diabetes (New York, N.Y.), 2022-09, Vol.71 (9), p.1979-1993

2022

Link zum Volltext

Verfügbarkeit prüfen

Immune Therapy and β-Cell Death in Type 1 Diabetes

Diabetes (New York, N.Y.), 2013-05, Vol.62 (5), p.1676-1680

2013

Link zum Volltext

Verfügbarkeit prüfen

Anti-CD3 mAbs for treatment of type 1 diabetes

Diabetes/metabolism research and reviews, 2009-05, Vol.25 (4), p.302-306

2009

Link zum Volltext

Verfügbarkeit prüfen

Effects of Autoimmunity and Immune Therapy on β-Cell Turnover in Type 1 Diabetes

Diabetes (New York, N.Y.), 2006-12, Vol.55 (12), p.3238-3245

2006

Link zum Volltext

Verfügbarkeit prüfen

Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes

Diabetes (New York, N.Y.), 2009-11, Vol.58 (11), p.2588-2595

2009

Link zum Volltext

Verfügbarkeit prüfen

A Humanized Mouse Model of Autoimmune Insulitis

Diabetes (New York, N.Y.), 2014-05, Vol.63 (5), p.1712-1724

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 84

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieDiabetes

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(84)

Sprache

Englisch
(84)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Diabetes
(41)
Endocrinology & Metabolism
(34)
Life Sciences & Biomedicine
(34)
Science & Technology
(34)
Humans
(33)
Biological And Medical Sciences
(25)
Medical Sciences
(25)
Type 1 Diabetes
(25)
Diabetes Mellitus
(24)
Endocrine Pancreas. Apud Cells
(23)
Endocrinopathies
(23)
Diabetes. Impaired Glucose Tolerance
(22)
Etiopathogenesis. Screening. Investigations. Target Tissue Resistance
(21)
Peptides
(21)
Insulin
(20)
Animals
(17)
Female
(16)
Male
(16)
Adult
(14)
Autoantibodies
(14)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Journals@Ovid Complete
(84)
EZB Free E-Journals
(83)
Single Journals
(83)
Wiley Online Library Journals
(1)
Wiley Online Library Full Collection 2018
(1)

Zeitschrift / Serie

Diabetes/metabolism Research And Reviews
(1)

Menü

Weitere Dienste

Einstellungen

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

The β-Cell in Type 1 Diabetes Pathogenesis: A Victim of Circumstances or an Instigator of Tragic Events?

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes

731-P: The Effect of Abatacept upon Glucose and C-Peptide Endpoints at One Year of Treatment and on Follow-up

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Natural History of β-Cell Function in Type 1 Diabetes

Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances

A Call for Improved Reporting of Human Islet Characteristics in Research Articles

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protégé Trial

Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective

Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade: Evidence of Improved Immune Regulation

276-OR: A 2-Dimensional (2D) Analysis of Glucose and C-Peptide Shows a Teplizumab Effect in Individuals at Risk for Type 1 Diabetes (T1D) 3 Months after Treatment

11-OR: Assessments of Prediagnostic Metabolic Measures as Surrogate Endpoints for Type 1 Diabetes (T1D) Prevention Trials

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience

β-Cell Mass and Type 1 Diabetes : Going, Going, Gone?

How Does Type 1 Diabetes Develop?: The Notion of Homicide or β-Cell Suicide Revisited

Indirect and Direct Effects of SARS-CoV-2 on Human Pancreatic Islets

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials

Carbonyl Posttranslational Modification Associated With Early-Onset Type 1 Diabetes Autoimmunity

Immune Therapy and β-Cell Death in Type 1 Diabetes

Anti-CD3 mAbs for treatment of type 1 diabetes

Effects of Autoimmunity and Immune Therapy on β-Cell Turnover in Type 1 Diabetes

Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes

A Humanized Mouse Model of Autoimmune Insulitis

Aktive Filter

Suchergebnisse filtern